Patents by Inventor Robert Hett

Robert Hett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250120958
    Abstract: The invention relates to a compound of formula (I), for use in treating GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. Specifically, the invention relates to a compound of formula (I) for use in increasing survival of a subject suffering from GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. The compound of formula (I) may also be used as an anti-inflammatory agent.
    Type: Application
    Filed: January 10, 2023
    Publication date: April 17, 2025
    Inventors: Jennifer Robin, Fritz Blatter, Robert Hett, Kyle Landskroner
  • Publication number: 20250059137
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: August 30, 2024
    Publication date: February 20, 2025
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Patent number: 12195455
    Abstract: The invention relates to succinic acid addition salts or fumaric acid addition salts of piperazine derivatives of formula (I), as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: January 14, 2025
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Robert Hett, David Malcolm Crowe
  • Patent number: 12116344
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: October 15, 2024
    Assignee: Azafaros B.V.
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Publication number: 20240287001
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: October 1, 2021
    Publication date: August 29, 2024
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Patent number: 11891350
    Abstract: The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)-(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to the treatment or prophylaxis of pain, inflammation and/or autoimmunity and provides a method of treating or preventing pain, inflammation and/or autoimmunity as well as the use of this polymorphic form in the manufacture of medicaments for the treatment or prophylaxis of pain (preferably nociceptive or neuropathic), inflammation and/or autoimmunity in humans and/or non-human animals.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: February 6, 2024
    Assignee: Novaremed Ltd.
    Inventors: Eli Kaplan, Robert Hett
  • Publication number: 20230391724
    Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.
    Type: Application
    Filed: October 1, 2021
    Publication date: December 7, 2023
    Inventors: Robert Hett, Fritz Blatter, Jennifer Robin, Kyle Landskroner
  • Publication number: 20220204558
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 30, 2022
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Kulkami, Young Lo, Stephen Munk, I. Fraser Pickersgill
  • Publication number: 20220002228
    Abstract: The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)-(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to the treatment or prophylaxis of pain, inflammation and/or autoimmunity and provides a method of treating or preventing pain, inflammation and/or autoimmunity as well as the use of this polymorphic form in the manufacture of medicaments for the treatment or prophylaxis of pain (preferably nociceptive or neuropathic), inflammation and/or autoimmunity in humans and/or non-human animals.
    Type: Application
    Filed: January 22, 2020
    Publication date: January 6, 2022
    Inventors: Eli KAPLAN, Robert HETT
  • Publication number: 20210395301
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 23, 2021
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Kulkarni, Young Lo, Stephen Munk, I. Fraser Pickersgill
  • Publication number: 20210198250
    Abstract: The invention relates to succinic acid addition salts or fumaric acid addition salts of piperazine derivatives of formula (I), as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glucosidase inhibitors.
    Type: Application
    Filed: August 22, 2019
    Publication date: July 1, 2021
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Robert HETT, David Malcolm CROWE
  • Publication number: 20210171574
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Kulkarni, Young Lo, Stephen Munk, I. Fraser Pickersgill
  • Publication number: 20200369722
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Kulkarni, Young Lo, Stephen Munk, I. Fraser Pickersgill
  • Publication number: 20200157143
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Lulkarni, Young Lo, Stephen Munk, I.Fraser Pickersgill
  • Publication number: 20190330270
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: July 11, 2019
    Publication date: October 31, 2019
    Inventors: Vince Ammoscato, John E. Bishop, Fang-Ting Chiu, Achim Geiser, Jean-Marc Gomez, Robert Hett, Christoph Koellner, Vithalanand R. Kulkarni, Young Lo, Stephen Munk, I. Fraser Pickersgill
  • Publication number: 20190112334
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 18, 2019
  • Publication number: 20180265546
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
  • Patent number: 10000529
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 19, 2018
  • Publication number: 20180044377
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Application
    Filed: September 22, 2017
    Publication date: February 15, 2018
  • Patent number: 9862745
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 9, 2018